The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 42302749.
- Also identified by DOI 10.1016/j.xcrm.2026.102790.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor heterogeneity and evolution constrain NSCLC immunotherapy, leading to variable and often short-lived responses. This commentary discusses the ARPA-H ADAPT program and IMMUNO-BIOMAP trial, which longitudinally profile tumors and the microenvironment to identify resistance mechanisms in real time and enable adaptive, biomarker-guided, personalized treatment strategies.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Biomarkers, Tumor
- Immunotherapy